JPWO2021225159A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021225159A5
JPWO2021225159A5 JP2022519631A JP2022519631A JPWO2021225159A5 JP WO2021225159 A5 JPWO2021225159 A5 JP WO2021225159A5 JP 2022519631 A JP2022519631 A JP 2022519631A JP 2022519631 A JP2022519631 A JP 2022519631A JP WO2021225159 A5 JPWO2021225159 A5 JP WO2021225159A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
sequence shown
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022519631A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021225159A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2021/017479 external-priority patent/WO2021225159A1/ja
Publication of JPWO2021225159A1 publication Critical patent/JPWO2021225159A1/ja
Publication of JPWO2021225159A5 publication Critical patent/JPWO2021225159A5/ja
Pending legal-status Critical Current

Links

JP2022519631A 2020-05-08 2021-05-07 Pending JPWO2021225159A1 (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020082653 2020-05-08
PCT/JP2021/017479 WO2021225159A1 (ja) 2020-05-08 2021-05-07 Gitr結合性分子

Publications (2)

Publication Number Publication Date
JPWO2021225159A1 JPWO2021225159A1 (https=) 2021-11-11
JPWO2021225159A5 true JPWO2021225159A5 (https=) 2023-03-02

Family

ID=78467973

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022519631A Pending JPWO2021225159A1 (https=) 2020-05-08 2021-05-07

Country Status (2)

Country Link
JP (1) JPWO2021225159A1 (https=)
WO (1) WO2021225159A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618632B2 (en) * 2003-05-23 2009-11-17 Wyeth Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies
SI3148579T1 (sl) * 2014-05-28 2021-07-30 Agenus Inc. Proti GITR antitelesa in postopki z njihovo uporabo
RU2017115315A (ru) * 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
AU2016334623A1 (en) * 2015-10-07 2018-02-15 F. Hoffmann-La Roche Ag Bispecific antibodies with tetravalency for a costimulatory TNF receptor
CN110869392A (zh) * 2017-05-16 2020-03-06 百时美施贵宝公司 用抗gitr激动性抗体治疗癌症

Similar Documents

Publication Publication Date Title
JP2025160458A5 (https=)
JP2023504572A5 (https=)
JP2019054802A5 (https=)
JP2024504384A5 (https=)
JP2021502984A5 (https=)
JP2009225799A5 (https=)
JP2024167313A5 (https=)
JP2022512132A5 (https=)
JP2021530251A5 (https=)
JP2022521551A5 (https=)
JP2020536504A5 (https=)
JP2018516853A5 (https=)
FI2726510T3 (fi) Kaksoiskohdennus
RU2018133708A (ru) Антитела, обладающие специфичностью к btla, и их использование
JP2018516554A5 (https=)
FI3322727T3 (fi) Humanisoituja tai kimeerisiä CD3-vasta-aineita
JP2023540526A5 (https=)
JP2023520969A5 (https=)
RU2021103288A (ru) МОЛЕКУЛЫ СО СПЕЦИФИЧНОСТЬЮ В ОТНОШЕНИИ CD79 и CD22
JP2018505681A5 (https=)
JP2023525695A5 (https=)
JP2021530244A5 (https=)
JP2023509373A5 (https=)
JP2024512135A5 (https=)
JP2015514068A5 (https=)